Global Anti-Bacterial Drugs Market is Forecast to Reach US$ 49,871.0 Million by 2019; CAGR of 3.1% from 2015 to 2019

Asia-Pacific is expected to be the most potential market with CAGR of 5.6% for 2015-2019, whereas Europe is estimated to be the slowest of the six regions and is anticipated to grow at a CAGR of 1.4% from 2015 to 2019. End Quote

Daptomycin & Linezolid are the reigning blockbuster molecules on the market with revenues of US$ 1,052.9 million and US$ 1,352.0 millions in 2014.

(1888PressRelease) July 07, 2015 - SA-BRC analysts monitored trends in the antibacterial drugs market across several types of anti-bacterial classes such as Beta-lactams, Macrolides, Tetracyclines, Quinolones, Aminoglycosides, Sulfonamides, Glycopeptides and Oxazolidinones. Infections caused by antibiotic-resistant bacteria, or "ESKAPE" pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), cause significant morbidity and mortality. The current market for branded anti-bacterial drugs looks positive for patients owing the intense competition from generics and expiration of several patents since the last decade. Along with this, more affordable therapy for multiple drug resistant pathogens will become available to patients with increasing number of generics.

To read further, please visit: http://www.sa-brc.com/publish-global-anti-bacterial.php

Until recently, the antibacterial pipeline was considered to be completely dry with very few foreseen launches, however 2014-2015 saw five major launches with another 8 expected by the turn of the decade. The largest challenge for drug manufacturers was to overcome a barrage of highly drug-resistant superbugs that have been observed across hospitals across the world. Improper usage, dosage and treatment regimen followed by patients has now created significant damage in terms of health since drug-resistant bacteria are difficult to deal with using conventional pharmaceuticals.

Cubist Pharmaceuticals had very good years with several key acquisitions paying out well which included the acquisition of Trius Therapeutics in 2013. Optimer Pharmaceuticals, Trius Therapeutics, Cubist Pharmaceuticals and Cempra now considered the richest sources of antibacterials along with other players such as Nektar Pharmaceuticals and Mpex. It is sad to acknowledge that even with increasing incentive based R&D regulations such as GAIN Act, several companies are readjusting focus to other areas even after the visibility of avenues to progress and improve the antibiotic field. A harsh illustration of this is that of Cubist with a successful antibiotic discovery department that within months of being acquired slashed the entire drug discovery department.

###

Visit Sa-brc Website

space